Marine Collagen Hydrolysates Promote Collagen Synthesis, Viability and Proliferation While Downregulating the Synthesis of Pro-Catabolic Markers in Human Articular Chondrocytes.
Cartilage is a non-innervated and non-vascularized tissue. It is composed of one main cell type, the chondrocyte, which governs homeostasis within the cartilage tissue, but has low metabolic activity. Articular cartilage undergoes substantial stresses that lead to chondral defects, and inevitably osteoarthritis (OA) due to the low intrinsic repair capacity of cartilage. OA remains an incurable degenerative disease. In this context, several dietary supplements have shown promising results, notably in the relief of OA symptoms. In this study, we investigated the effects of collagen hydrolysates derived from fish skin (Promerim®30 and Promerim®60) and fish cartilage (Promerim®40) on the phenotype and metabolism of human articular chondrocytes (HACs). First, we demonstrated the safety of Promerim® hydrolysates on HACs cultured in monolayers. Then we showed that, Promerim® hydrolysates can increase the HAC viability and proliferation, while decreasing HAC SA-β-galactosidase activity. To evaluate the effect of Promerim® on a more relevant model of culture, HAC were cultured as organoids in the presence of Promerim® hydrolysates with or without IL-1β to mimic an OA environment. In such conditions, Promerim® hydrolysates led to a decrease in the transcript levels of some proteases that play a major role in the development of OA, such as Htra1 and metalloproteinase-1. Promerim® hydrolysates downregulated HtrA1 protein expression. In contrast, the treatment of cartilage organoids with Promerim® hydrolysates increased the neosynthesis of type I collagen (Promerim®30, 40 and 60) and type II collagen isoforms (Promerim®30 and 40), the latter being the major characteristic component of the cartilage extracellular matrix. Altogether, our results demonstrate that the use of Promerim® hydrolysates hold promise as complementary dietary supplements in combination with the current classical treatments or as a preventive therapy to delay the occurrence of OA in humans.
['Bourdon|Bastien|B|0000-0003-0185-9143', 'Cassé|Frédéric|F|', 'Gruchy|Nicolas|N|', 'Cambier|Pierre|P|', 'Leclercq|Sylvain|S|', 'Oddoux|Sarah|S|0000-0002-2888-8430', 'Noël|Antoine|A|', 'Lafont|Jérôme E|JE|0000-0001-8313-9873', 'Contentin|Romain|R|0000-0001-5917-7298', 'Galéra|Philippe|P|0000-0002-7797-2284']
D002358:Cartilage, Articular D002465:Cell Movement D049109:Cell Proliferation D016922:Cellular Senescence D019902:Chondrocytes D004353:Drug Evaluation, Preclinical D006801:Humans D010003:Osteoarthritis D061251:Primary Cell Culture
collagen collagen hydrolysates osteoarthritis catabolic markers human chondrocytes in vitro repair interleukin-1 matrix-associated autologous chondrocyte implantation (MACI) senescence